Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [3]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [3]. Group 2: Recovery Information - Shareholders who experienced losses in MoonLake stock during the specified timeframe are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [4][6]. - Interested parties can find more information and submit claims through the provided link [4][6]. Group 3: Legal Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].